Linifanib
As of the edition of 20 October 2026, Linifanib is a small molecule: stopped in 2021; acts on CSF1R, FLT1 and FLT3 and 4 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2021
- Kind
- Small molecule
- Registered trials
- 18, 6 stopped early
- Disease areas
- Cancer; Lungs and airways; Digestive system; Pregnancy and women's health; Urinary and reproductive; Eye
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
23 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product23 company-target rows are on route A because of Linifanib.
See the 23 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| CSF1R | Macrophage colony-stimulating factor 1 receptor | P07333 |
| PDGFRB | Platelet-derived growth factor receptor beta | P09619 |
| PDGFRA | Platelet-derived growth factor receptor alpha | P16234 |
| FLT1 | Vascular endothelial growth factor receptor 1 | P17948 |
| FLT4 | Vascular endothelial growth factor receptor 3 | P35916 |
| KDR | Vascular endothelial growth factor receptor 2 | P35968 |
| FLT3 | Receptor-type tyrosine-protein kinase FLT3 | P36888 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 10 | 7 | 0 | 3 |
| Phase 2 | 7 | 5 | 0 | 2 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 18 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| AbbVie | Lead sponsor of trials | 2007 to now |
| Abbott | Lead sponsor of trials | 2008 to now |
| Alcon | Lead sponsor of trials | 2010 to now |
| BioGene Pharmaceutical | Lead sponsor of trials | 2021 to now |